Healthcare Business

Pills

What to Expect From Merck and Pfizer Earnings

Pharmaceutical giants Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) are both releasing their first quarter financial results Tuesday before the markets open. Each of these companies ...
Read Full Story »
generic drugs

Key Analyst Sees Nearly 30% Upside in Ironwood

With the health care sector still on fire this year, Merrill Lynch brings another company to the forefront that it considers a buy. Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) is viewed ...
Read Full Story »
145922793

A Real Heartbreak for Celladon

On its website, Celladon Corp. (NASDAQ: CLDN) writes “Hope to Heart Patients.” Not to sound morbid, but the company appears to have lost at least some hope – in terms of dollars ...
Read Full Story »
Biotechnology word cloud

Short Sellers Become More Wary of Big Biotech

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Wall St Bull statue

Will Biogen Earnings Interrupt the Biotech Bull Market?

Biogen Inc. (NASDAQ: BIIB) reported its first-quarter financials before the markets opened Friday. The biotech giant had $3.82 in earnings per share (EPS) on $2.55 billion in revenue, versus Thomson ...
Read Full Story »
upgrade

GW Pharma Gets Big Analyst Upgrade Into Cannabinoid FDA Orphan Drug Designation

GW Pharmaceuticals PLC (NASDAQ: GWPH) was recently listed as the top medical marijuana stock for National Weed Day, but other things are going on here besides weird holidays. GW recently ...
Read Full Story »
generic drugs

Amgen Earnings Point to More Froth in the Biotech Sector

Amgen Corp. (NASDAQ: AMGN) reported first-quarter 2015 earnings Tuesday afternoon after equity markets had closed. The biotech firm posted adjusted earnings per share (EPS) of $2.48 on revenues of $5.03 ...
Read Full Story »
biotech

Will Amgen Earnings Shape Biotech for the Rest of 2015?

After markets close on Tuesday, Amgen Inc. (NASDAQ: AMGN) is scheduled to announce its first-quarter results. Among biotech companies Amgen is the second-largest measured by market cap, trailing only Gilead ...
Read Full Story »
145922793

Can La Jolla Pharma Shares Really Double?

Health care is still going strong in April, and biotech and emerging pharmaceutical stocks still have huge gains so far in 2015. La Jolla Pharmaceutical Co. (NASDAQ: LJPC) has seen ...
Read Full Story »
Prescription drugs

Why Teva Really Wants to Acquire Mylan

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has just approached Mylan N.V. (NASDAQ: MYL) with a public takeover bid valued at $82 per share in cash and stock. The offering would consist ...
Read Full Story »
research

BioCryst Upgrade Almost Looks Misunderstood

The most recent analyst call by Merrill Lynch for BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) may be very misunderstood for what it is. The brokerage firm upgraded BioCryst to Neutral and ...
Read Full Story »
DNA

Genetic Technologies Drives Ahead in the Fight Against Cancer

Genetic Technologies Limited (NASDAQ: GENE) has been making large strides in the area of women’s health recently with the opening of more centers that utilize the BREVAGenplus. Ultimately this will ...
Read Full Story »
knees

Is Ampio at Risk of Imploding?

Companies in the biotech and pharmaceuticals field are generally riskier than other companies because a single failed study could make or break the company, similar to what happened with Ampio ...
Read Full Story »
marijuana leaf

Is GW Pharmaceuticals the Perfect Cannabis Stock on National Weed Day?

With Monday, April 20, being National Weed Day (a 4:20 takeoff), 24/7 Wall St. wondered which marijuana stocks were either the best in class or had the most upside. The ...
Read Full Story »
Pills

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

One thing investors look for in an aging bull market, especially one trading near all-time highs, is rising earnings. That is the only way to justify multiples that creep up ...
Read Full Story »